Intranasal administration of Escherichia coli Nissle expressing the spike protein of SARS-CoV-2 induces long-term immunization and prevents spike protein-mediated lung injury in mice.

COVID-19 Engineered probiotics IgA Intranasal vaccine Mice lung injury NLRP3 Spike protein

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
21 Mar 2024
Historique:
received: 23 02 2024
revised: 13 03 2024
accepted: 15 03 2024
medline: 23 3 2024
pubmed: 23 3 2024
entrez: 22 3 2024
Statut: aheadofprint

Résumé

While current anti-Spike protein (SP) vaccines have been pivotal in managing the pandemic, their limitations in delivery, storage, and the inability to provide mucosal immunization (preventing infections) highlight the ongoing necessity for research and innovation. To tackle these constraints, our research group developed a bacterial-based vaccine using a non-pathogenic E. coli Nissle 1917 (EcN) strain genetically modified to express the SARS-CoV-2 spike protein on its surface (EcN-pAIDA1-SP). We intranasally delivered the EcN-pAIDA1-SP in two doses and checked specific IgG/IgA production as well as the key immune mediators involved in the process. Moreover, following the initial and booster vaccine doses, we exposed both immunized and non-immunized mice to intranasal delivery of SARS-CoV-2 SP to assess the effectiveness of EcN-pAIDA1-SP in protecting lung tissue from the inflammation damage. We observed detectable levels of anti-SARS-CoV-2 spike IgG in serum samples and IgA in bronchoalveolar lavage fluid two weeks after the initial treatment, with peak concentrations in the respective samples on the 35th day. Moreover, immunoglobulins displayed a progressively enhanced avidity index, suggesting a selective binding to the spike protein. Finally, the pre-immunized group displayed a decrease in proinflammatory markers (TLR4, NLRP3, ILs) following SP challenge, compared to the non-immunized groups, along with better preservation of tissue morphology. Our probiotic-based technology provides an effective immunobiotic tool to protect individuals against disease and control infection spread.

Identifiants

pubmed: 38518597
pii: S0753-3322(24)00325-1
doi: 10.1016/j.biopha.2024.116441
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116441

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Giovanni Sarnelli (G)

Department of Clinical Medicine and Surgery, Section of Gastroenterology, University Federico II, Naples 80138, Italy; Nextbiomics S.R.L. (Società a Responsabilità Limitata), Naples 80100, Italy. Electronic address: sarnelli@unina.it.

Alessandro Del Re (A)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome 00185, Italy. Electronic address: alessandro.delre@uniroma1.it.

Irene Palenca (I)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome 00185, Italy. Electronic address: irene.palenca@uniroma1.it.

Silvia Basili Franzin (SB)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome 00185, Italy. Electronic address: silvia.basilifranzin@uniroma1.it.

Jie Lu (J)

Nextbiomics S.R.L. (Società a Responsabilità Limitata), Naples 80100, Italy; Department of Anatomy and Cell Biology, China Medical University, Shenyang 110122, China. Electronic address: lvjie@cmu.edu.cn.

Luisa Seguella (L)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome 00185, Italy. Electronic address: luisa.seguella@uniroma1.it.

Aurora Zilli (A)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome 00185, Italy. Electronic address: aurora.zilli@uniroma1.it.

Marcella Pesce (M)

Department of Clinical Medicine and Surgery, Section of Gastroenterology, University Federico II, Naples 80138, Italy.

Sara Rurgo (S)

Department of Clinical Medicine and Surgery, Section of Gastroenterology, University Federico II, Naples 80138, Italy. Electronic address: sara.rurgo@unina.it.

Giovanni Esposito (G)

Nextbiomics S.R.L. (Società a Responsabilità Limitata), Naples 80100, Italy; Department of Molecular Medicine and Medical Biotechnologies, Centro Ingegneria Genetica-Biotecnologie Avanzate s.c.a rl, Naples 80131, Italy. Electronic address: espogiov@unina.it.

Walter Sanseverino (W)

Nextbiomics S.R.L. (Società a Responsabilità Limitata), Naples 80100, Italy. Electronic address: wsanseverino@sequentiabiotech.com.

Giuseppe Esposito (G)

Nextbiomics S.R.L. (Società a Responsabilità Limitata), Naples 80100, Italy; Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome 00185, Italy. Electronic address: giuseppe.esposito@uniroma1.it.

Classifications MeSH